The tweet was deleted by the author.
But we saved everything 🙂.
A new study referenced by Accuray reports that, in pancreatic stereotactic body radiotherapy (SBRT) using CyberKnife and Synchrony, the proximity of treatment targets to organs at risk (OARs) is a critical predictor of OAR dose exposure.
The research, published in the International Journal of Radiation Oncology, Biology, Physics, further reveals that changes in the shape and location of OARs between treatment sessions, known as inter-fraction deformation, have a greater impact on dose risk than residual tracking uncertainties within individual treatments. These findings highlight the complex challenges of ensuring safe dosing in pancreatic SBRT and may inform new protocols for clinical practice.
Accuray has previously reported that helical TomoTherapy delivers lower rates of xerostomia than VMAT in advanced nasopharyngeal carcinoma, citing improved sparing of the parotid glands in a recent study. At ESTRO26, the company also showcased its Radixact and Helix systems for flexible helical radiotherapy, expanding options in precision cancer treatment according to a previous announcement. These developments reflect Accuray’s continued focus on technology-driven advances in radiation therapy.